Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (Agkistrodon contortrix contortrix). It is a small protein that... 1992). Alfimeprase is being developed by Nuvelo.
- Mechanism
- Curator reviewed
When delivered locally at the site of a blood clot, alfimeprase has the potential, through a unique mechanism of action, to directly and rapidly degrade fibrin, a protein that provides the scaffolding for blood clots. In addition, alfimeprase's thrombolytic activity appears to be localized to the site of delivery because it is rapidly inactivated by alpha-2 macroglobulin, a naturally occurring protein in the blood, as it moves away from the site of delivery and into the general blood circulation.
- Primary indication
- Alfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).Curator reviewed
- Also known as
- 3-203-FIBROLASE (3-SERINE) (AGKISTRODON CONTORTRIX CONTORTRIX RECOMBINANT)
Resolves to
What you can answer from here — as of September 30, 2023
Which drugs share a target with Alfimeprase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account